Entering text into the input field will update the search result below

Branch of NIH to initiate mid-stage trial of BiondVax's flu vaccine candidate; shares up 37% premarket

Sep. 02, 2015 8:40 AM ETScinai Immunotherapeutics Ltd. (SCNI) StockBy: Douglas W. House, SA News Editor
  • The National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID) plans to launch a Phase 2 study in the U.S. in 2016 to assess BiondVax's (NASDAQ:BVXV) universal flu vaccine candidate, Multimeric-001 (M-001) as a primer vaccine to be administered several weeks before a pandemic vaccine to the H7N9 avian strain. The study will also investigate M-001's priming capacity to other seasonal and pandemic strains.
  • A strain-specific flu vaccine usually takes four to six months to manufacture, during which the disease can spread rapidly. Stockpiling M-001 as a pandemic primer would enable vaccinations to begin immediately.
  • An upcoming trial in Europe will assess M-001 as a primer to the H5N1 avian pandemic vaccine.
  • BVXV shares are up 37% premarket on robust volume.

Recommended For You

More Trending News

About SCNI Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SCNI--
Scinai Immunotherapeutics Ltd.